The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth (CMT) disease research aimed at bringing treatments to patients, announced today an investment of $450K into a new scientific approach for CMT1A and CMT1B, two common forms of the disease. ...
Charcot-Marie-Tooth Association (CMTA) Alliance Partner, NMD Pharma, announced the publication of comprehensive data sets demonstrating for the first time the ability of CIC-1 inhibition to restore muscle function in patients suffering from neuromuscular junction (NMJ) transmission deficits. These data are ...
The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth disease (CMT) research aimed at bringing treatments and a cure to patients, is pleased to announce the appointment of Bernard Coulie, M.D., Ph.D., and Kevin Marks to its Board of ...
The CMTA’s new $200K+ investment accelerates CMT1A organoid research, revolutionizing treatment evaluation for Charcot-Marie-Tooth disease (CMT)
GLENOLDEN, PENNSYLVANIA, USA, February 21, 2024 — The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth disease (CMT) research aimed at bringing treatments and ...
It is with the heaviest of hearts that the Charcot-Marie-Tooth Association (CMTA) mourns the loss of our friend and Strategy to Accelerate Research (STAR) Scientific Advisory Board (SAB) Member, Dr. M. Laura Feltri. Dr. Feltri passed away December 25, 2023, ...